Animal models of Alzheimer's disease and drug development.

Animal disease models are considered important in the development of drugs for Alzheimer's disease. This brief review will discuss possible reasons why their success in identifying efficacious treatments has been limited, and will provide some thoughts on the role of animal experimentation in drug development. Specifically, none of the current models of Alzheimer's disease have either construct or predictive validity, and no model probably ever will. Clearly, specific animal experiments contribute to our understanding of the disease and generate hypotheses. Ultimately, however, the hypothesis can only be tested in human patients and only with the proper tools. These tools are a pharmacologically active intervention (in humans) and a clinical trial suited to evaluate the mechanism of action. Integration of knowledge in quantitative (sub) models is considered important if not essential in this process.

[1]  P. Willner.  Validation criteria for animal models of human mental disorders: Learned helplessness as a paradigm case , 1986, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  Xulun Zhang,et al.  Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2010, Neuron.

[3]  J. de Magalhães,et al.  A database of vertebrate longevity records and their relation to other life‐history traits , 2009, Journal of evolutionary biology.

[4]  Michael Borrie,et al.  A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease , 2004, Journal of the American Geriatrics Society.

[5]  Wende Li,et al.  A nonhuman primate model of Alzheimer’s disease generated by intracranial injection of amyloid-beta42 and thiorphan , 2010, Metabolic Brain Disease.

[6]  D. Morgan.  Immunotherapy for Alzheimer’s disease , 2011, Journal of internal medicine.

[7]  C T Dollery.  The Challenge of Complexity , 2010, Clinical pharmacology and therapeutics.

[8]  E. Speretta,et al.  Testing the Therapeutic Potential of Doxycycline in a Drosophila melanogaster Model of Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[9]  J. Buccafusco.  Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders. , 2008, Journal of Alzheimer's disease : JAD.

[10]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[11]  M. Hutton,et al.  Oral Treatment with a γ-Secretase Inhibitor Improves Long-Term Potentiation in a Mouse Model of Alzheimer's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.

[12]  U. Ebert,et al.  Scopolamine model of dementia: electroencephalogram findings and cognitive performance , 1998, European journal of clinical investigation.

[13]  A. Extance.  Alzheimer's failure raises questions about disease-modifying strategies , 2010, Nature Reviews Drug Discovery.

[14]  Todd E. Golde,et al.  Targeting Aβ and tau in Alzheimer's disease, an early interim report , 2010, Experimental Neurology.

[15]  K. Jishage,et al.  Depletion of Vitamin E Increases Amyloid β Accumulation by Decreasing Its Clearances from Brain and Blood in a Mouse Model of Alzheimer Disease* , 2009, The Journal of Biological Chemistry.

[16]  G. M. Cole,et al.  Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology , 2001, Neurobiology of Aging.

[17]  Scott R. Barnum,et al.  INFLAMMATION AND ALZHEIMERS DISEASE , 2000 .

[18]  F. Aboitiz,et al.  Human-like rodent amyloid-β-peptide determines Alzheimer pathology in aged wild-type Octodon degu , 2005, Neurobiology of Aging.

[19]  Elizabeth Head,et al.  The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. , 2008, Journal of Alzheimer's disease : JAD.

[20]  G. McKhann,et al.  Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease , 2008, Nature Medicine.

[21]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[22]  Koichi M Iijima,et al.  Drosophila models of Alzheimer's amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-beta 42. , 2008, Journal of Alzheimer's disease : JAD.

[23]  D. Howells,et al.  Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.

[24]  T. Robbins,et al.  Selective lesions of the dorsomedial striatum impair serial spatial reversal learning in rats , 2010, Behavioural Brain Research.

[25]  P. Sachdev,et al.  Recent rodent models for Alzheimer’s disease: clinical implications and basic research , 2012, Journal of Neural Transmission.

[26]  A. Björklund,et al.  Cholinergic ventral forebrain grafts into the neocortex improve passive avoidance memory in a rat model of Alzheimer disease. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Krause,et al.  Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease? , 2006, Genes, brain, and behavior.

[28]  G. Jackson,et al.  Drosophila models of neurodegenerative disease , 2005, NeuroRX.

[29]  E. Kunkel.  Systems biology in drug discovery , 2004, Nature Biotechnology.

[30]  N. Tabet,et al.  Vitamin E for Alzheimer's disease and mild cognitive impairment. , 2008, The Cochrane database of systematic reviews.

[31]  T. Ahmed,et al.  Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease , 2010, Neuroscience.

[32]  R. Hargreaves,et al.  Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[33]  Oscar L. Lopez,et al.  Dementia and Alzheimer’s Disease , 2012 .

[34]  A. Lockhart,et al.  Monitoring the amyloid beta-peptide in vivo--caveat emptor. , 2009, Drug discovery today.

[35]  H. Geerts.  Bridging the Translational Disconnect in CNS Drug Discovery , 2009 .

[36]  C. Duyckaerts,et al.  Alzheimer disease models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.

[37]  S. Little,et al.  Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. , 1991, Brain research. Molecular brain research.

[38]  Carolyn A. Coughlan,et al.  Effects of donepezil on amyloid-β and synapse density in the Tg2576 mouse model of Alzheimer's disease , 2009, Brain Research.

[39]  P. Jeffrey,et al.  Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo , 2007 .

[40]  A. Klug,et al.  Tau protein, the paired helical filament and Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[41]  A. Aderem.  Systems Biology: Its Practice and Challenges , 2005, Cell.

[42]  J. Picq.  Aging affects executive functions and memory in mouse lemur primates , 2007, Experimental Gerontology.

[43]  G J Hademenos,et al.  Principles and philosophy of modeling in biomedical research. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  J. Rusted,et al.  Vitamin E for Alzheimer's dementia and mild cognitive impairment. , 2012, The Cochrane database of systematic reviews.

[45]  D. Schenk.  Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning , 2002, Nature Reviews Neuroscience.

[46]  ハジト エルダー‐フィンケルマン，.  Glycogen synthase kinase-3 inhibitors , 2004 .

[47]  E. Check.  Nerve inflammation halts trial for Alzheimer's drug , 2002, Nature.

[48]  B. Jenkins,et al.  Anti-inflammatory treatment in AD mice protects against neuronal pathology , 2010, Experimental Neurology.

[49]  P. Jeffrey,et al.  Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. , 2007, Journal of neurochemistry.

[50]  M. Dhenain,et al.  Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments , 2012, Neurobiology of Aging.

[51]  Beate Gerstbrein,et al.  Dying for a cause: invertebrate genetics takes on human neurodegeneration , 2003, Nature Reviews Genetics.

[52]  D. Sparks,et al.  Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease , 2010, Neurology.

[53]  F. Petit,et al.  Age-associated cerebral atrophy in mouse lemur primates , 2011, Neurobiology of Aging.

[54]  G. Cole,et al.  GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals , 2009, Neurobiology of Disease.

[55]  H. Annoura,et al.  Progressive brain dysfunction following intracerebroventricular infusion of beta1–42-amyloid peptide , 2001, Brain Research.

[56]  B. Imbimbo.  An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease , 2009, Expert opinion on investigational drugs.

[57]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[58]  E. Berg.  Systems biology in drug discovery and development. , 2014, Drug discovery today.

[59]  S. Nam,et al.  Inflammation and Alzheimer’s disease , 2010, Archives of pharmacal research.

[60]  J. Schnabel.  Amyloid: Little proteins, big clues , 2011, Nature.

[61]  M. Staufenbiel,et al.  APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. , 2002, Biochemistry.

[62]  David F. Horrobin,et al.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.

[63]  D. Van Dam,et al.  Animal models in the drug discovery pipeline for Alzheimer's disease , 2011, British journal of pharmacology.

[64]  Ana Martínez,et al.  Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment , 2011, International journal of Alzheimer's disease.

[65]  J. Marsh,et al.  Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons , 2009, Neurobiology of Disease.

[66]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[67]  H. Boxenbaum,et al.  Pharmacokinetics: philosophy of modeling. , 1992, Drug metabolism reviews.

[68]  J. Cummings,et al.  Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology , 2011, BMC neurology.

[69]  J. Schnabel.  Little proteins, big clues , 2011 .

[70]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[71]  David H. Cribbs and Michael G. Agadjanyan.  Immunotherapy for Alzheimers Disease: Potential Problems and Possible Solutions , 2005 .

[72]  O. Blin,et al.  The grey mouse lemur: A non-human primate model for ageing studies , 2012, Ageing Research Reviews.

[73]  O. Touloumi,et al.  Statins Reduce the Neurofibrillary Tangle Burden in a Mouse Model of Tauopathy , 2009, Journal of neuropathology and experimental neurology.

[74]  M. Dhenain,et al.  Regional atrophy in the brain of lissencephalic mouse lemur primates: Measurement by automatic histogram‐based segmentation of MR images , 2003, Magnetic resonance in medicine.

[75]  C. Bouras,et al.  Quantitative analysis of tau protein-immunoreactive accumulations and β amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus , 1997, Acta Neuropathologica.